Additionally, PATZ1 has been proposed as a diagnostic/prognostic biomarker in different neoplasia, including testicular germ cell tumors [24], renal cell carcinoma [25,26,27], CNS neoplasms [28,29,30], round cell sarcomas [31], large cell B lymphomas [32], thyroid cancer [20], and ovarian cancer [23], where lower levels and cytoplasmic localization of the PATZ1 protein are often predictive of a more aggressive phenotype and, consequently, the worst prognosis [20,23,28,32]. This evidence concerns the gene PATZ1 and renal cell carcinoma.